withanolide d has been researched along with cytochrome c-t in 1 studies
| Studies (withanolide d) | Trials (withanolide d) | Recent Studies (post-2010) (withanolide d) | Studies (cytochrome c-t) | Trials (cytochrome c-t) | Recent Studies (post-2010) (cytochrome c-t) |
|---|---|---|---|---|---|
| 25 | 0 | 11 | 11,809 | 21 | 5,125 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, K; Mallick, A; Mandal, C; Mondal, S; Sangwan, R | 1 |
1 other study(ies) available for withanolide d and cytochrome c-t
| Article | Year |
|---|---|
Bak compensated for Bax in p53-null cells to release cytochrome c for the initiation of mitochondrial signaling during Withanolide D-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Cytochromes c; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Signal Transduction; Tumor Suppressor Protein p53; Withanolides | 2012 |